Gilead Sciences Inc Stock Price, News & Analysis

Gilead Sciences (NASDAQ:GILD) has announced a significant $6.5 million commitment in STEM education grants through the Gilead Foundation. The funding includes a $1 million grant to Boys and Girls Clubs of America, $500,000 to San Mateo Foster City Education Foundation, and $5 million to San Francisco State University for their Science and Engineering Innovation Center.

This initiative aims to address the projected shortfall of 1.4 million skilled STEM workers by 2030 in the U.S., with STEM skills expected to be essential for 80% of all jobs by the end of the decade. The investment builds on Gilead's broader commitment to the Bay Area, where the company has awarded over $150 million in grant funding to nearly 250 nonprofit organizations since 2018.

Ensoma, backed by Gilead (NASDAQ:GILD), has secured a $53 million financing round from existing investors to advance its in vivo hematopoietic stem cell (HSC) engineering platform. The funding will primarily support the company's recently initiated Phase 1/2 clinical trial of EN-374 for X-linked chronic granulomatous disease (X-CGD), which is now open for patient enrollment.

The investment syndicate includes notable participants such as Gilead, 5AM Ventures, Gates Foundation, and Viking Global Investors. As part of the investment, Gilead has appointed an executive to Ensoma's board. The company aims to develop one-time, outpatient treatments for serious diseases, with additional focus areas in immuno-oncology and sickle cell disease.

Gilead Sciences (Nasdaq: GILD) has announced a groundbreaking partnership with PEPFAR and the Global Fund to provide lenacapavir, a twice-yearly injectable HIV prevention treatment, to up to 2 million people in low- and lower-middle-income countries over three years.

The company will provide the medication at no profit and has secured royalty-free agreements with six generic manufacturers covering 120 high-incidence countries. By end of 2025, Gilead plans to complete regulatory submissions in 18 countries representing 70% of the HIV burden in the covered region.

The initiative follows lenacapavir's recent U.S. approval (as Yeztugo®), European Commission authorization, and positive EU-M4all opinion. Gilead has submitted for WHO prequalification in August 2025, with expected conclusion by year-end.

Gilead Sciences (NASDAQ:GILD) has launched Choose U™, a global awareness campaign highlighting the experiences of people living with HIV. The initiative, unveiled at the 2025 United States Conference on HIV/AIDS, aims to destigmatize HIV and promote treatment adherence through authentic storytelling.

The campaign emphasizes the U=U (undetectable = untransmittable) movement and features real-world stories from individuals maintaining undetectable viral loads. Currently, only two-thirds of the estimated 40 million people living with HIV globally are virally suppressed. The initial wave includes three individual stories, with more than a dozen additional stories from six countries planned for release through 2026.

Gilead Sciences (NASDAQ:GILD) has broken ground on its new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California. The five-story, 180,000 square foot facility is part of the company's planned $32 billion U.S. investment through 2030, projected to generate over $43 billion in economic value.

The state-of-the-art facility will feature AI-enabled systems, autonomous robotics, and real-time digital monitoring, serving as a hub for innovation in biologics development. This expansion, along with two other facilities under construction, is expected to create over 3,000 direct and indirect jobs and strengthen Gilead's biologics capabilities, a key component of its growth strategy across virology, oncology, and inflammation.

Gilead Sciences (NASDAQ:GILD) has received European Commission (EC) marketing authorization for Yeytuo® (lenacapavir), the first and only twice-yearly injectable HIV prevention treatment in the EU. The authorization covers adults and adolescents weighing at least 35kg who are at increased risk of HIV-1 acquisition.

The approval is supported by two Phase 3 trials: PURPOSE 1 showed zero HIV infections among 2,134 participants, while PURPOSE 2 demonstrated 99.9% effectiveness with only two HIV infections among 2,179 participants. The EC's accelerated decision follows U.S. FDA approval in June and WHO guidelines recommendation in July.

Gilead is executing a global access strategy with regulatory filings in multiple countries and has partnered with The Global Fund to supply lenacapavir for up to two million people in low- and middle-income countries.

Kite, a Gilead (NASDAQ: GILD) subsidiary, has announced the acquisition of Interius BioTherapeutics for $350 million in cash. The acquisition focuses on Interius's innovative in vivo CAR therapeutics platform, which enables CAR T-cell generation directly within patients through a single intravenous infusion.

The platform eliminates the need for traditional cell harvesting, engineering, reinfusion, and preconditioning chemotherapy. The transaction is expected to impact Gilead's 2025 EPS by $0.23-$0.25. Interius's operations will be integrated into Kite's research team, establishing a center of excellence in Philadelphia for developing next-generation in vivo therapies.

Gilead Sciences (Nasdaq: GILD) has announced its participation in four major investor conferences in September 2025. The company's executives will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Annual Global Healthcare Conference (Sept 9), and Baird Global Healthcare Conference (Sept 10).

All presentations will be accessible via live webcasts on Gilead's investor relations website, with replays available for at least 30 days after each event.

Gilead Sciences (NASDAQ:GILD) reported strong Q2 2025 financial results with total revenue increasing 2% to $7.1 billion. Product sales excluding Veklury grew 4% to $6.9 billion, driven by HIV portfolio growth, particularly Biktarvy sales increasing 9% to $3.5 billion.

The company achieved diluted EPS of $1.56 and non-GAAP EPS of $2.01. Key highlights include FDA approval for Yeztugo as the first twice-yearly HIV prevention option and increased 2025 guidance. HIV product sales grew 7% to $5.1 billion, while Trodelvy sales increased 14% to $364 million.

Gilead raised its full-year 2025 guidance, now expecting product sales between $28.3-$28.7 billion and non-GAAP diluted EPS of $7.95-$8.25.